Skip to main content

Targeting the host–pathogen interface for treatment of Staphylococcus aureus infection

Seminars in Immunopathology volume 34, pages 299–315 (2012)Cite this article

Abstract

Recent emergence of methicillin-resistant Staphylococcus aureus both within and outside healthcare settings has accelerated the use of once reserved last line antibiotics such as vancomycin. With increased use of antibiotics, there has been a rapid rise in the rate of resistance development to the anti-MRSA drugs. As the antibiotic pipeline becomes strained, alternative strategies are being sought for future treatment of S. aureus. Here, we review several novel anti-staphylococcal strategies that, unlike conventional antibiotics, do not target essential gene products elaborated by the pathogen. The approaches seek instead to weaken the S. aureus defense by neutralizing its virulence factors or boosting host immunity. Other strategies target commensal bacteria that naturally colonize the human host to inhibit S. aureus colonization. Ultimately, the aim is to shift the balance between host defense and pathogen virulence in favor of inhibition of S. aureus pathogenic activities.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Chambers HF (2005) Community-associated MRSA—resistance and virulence converge. N Engl J Med 352(14):1485–1487

    PubMed  CAS  Google Scholar 

  2. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22):2976–2984

    PubMed  CAS  Google Scholar 

  3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763–1771

    PubMed  CAS  Google Scholar 

  4. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355(7):666–674

    PubMed  CAS  Google Scholar 

  5. Gould IM (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31(Suppl 2):1–9

    PubMed  CAS  Google Scholar 

  6. Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60(4):788–794

    PubMed  CAS  Google Scholar 

  7. Deresinski S (2007) Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence. Clin Infect Dis 44(12):1543–1548

    PubMed  CAS  Google Scholar 

  8. Nathan C (2004) Antibiotics at the crossroads. Nature 431(7011):899–902

    PubMed  CAS  Google Scholar 

  9. Mera R (2005) Predicting the future Streptococcus pneumoniae resistance landscape. Curr Opin Pharmacol 5(5):459–464

    PubMed  CAS  Google Scholar 

  10. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rumke HC, Verbrugh HA, Hermans PW (2004) Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 363(9424):1871–1872

    PubMed  CAS  Google Scholar 

  11. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3(12):948–958

    PubMed  CAS  Google Scholar 

  12. Liu GY (2009) Molecular pathogenesis of Staphylococcus aureus infection. Pediatr Res 65(5 Pt 2):71R–77R

    PubMed  Google Scholar 

  13. Gordon RJ, Lowy FD (2008) Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46(Suppl 5):S350–S359

    PubMed  CAS  Google Scholar 

  14. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJ, van Kessel KP, van Strijp JA (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 6(9):920–927

    PubMed  CAS  Google Scholar 

  15. Graves SF, Kobayashi SD, DeLeo FR (2010) Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J Mol Med (Berl) 88(2):109–114

    CAS  Google Scholar 

  16. Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials, Committee on New Directions in the Study of Antimicrobial Therapeutics:Immunomodulation, (2006). In: In Treating Infectious Diseases in a Microbial World:Report of Two Workshops on Novel Antimicrobial Therapeutics. National Academies Press., Washington D.C, pp 21–22

  17. Schaffer AC, Lee JC (2009) Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 23(1):153–171

    PubMed  Google Scholar 

  18. Otto M (2010) Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther 10(7):1049–1059

    PubMed  CAS  Google Scholar 

  19. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V (2005) Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 202(2):209–215

    PubMed  CAS  Google Scholar 

  20. Clauditz A, Resch A, Wieland KP, Peschel A, Gotz F (2006) Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect Immun 74(8):4950–4953

    PubMed  CAS  Google Scholar 

  21. Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E (2008) A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319(5868):1391–1394

    PubMed  CAS  Google Scholar 

  22. Song Y, Liu CI, Lin FY, No JH, Hensler M, Liu YL, Jeng WY, Low J, Liu GY, Nizet V, Wang AH, Oldfield E (2009) Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem 52(13):3869–3880

    PubMed  CAS  Google Scholar 

  23. Song Y, Lin FY, Yin F, Hensler M, Rodrigues Poveda CA, Mukkamala D, Cao R, Wang H, Morita CT, Gonzalez Pacanowska D, Nizet V, Oldfield E (2009) Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem 52(4):976–988

    PubMed  CAS  Google Scholar 

  24. Foster TJ, Hook M (1998) Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 6(12):484–488

    PubMed  CAS  Google Scholar 

  25. Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM (2006) Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50(2):511–518

    PubMed  CAS  Google Scholar 

  26. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184(12):1572–1580

    PubMed  CAS  Google Scholar 

  27. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, Edwards JE Jr (2008) The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 76(10):4574–4580

    PubMed  CAS  Google Scholar 

  28. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S (2007) Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151(3):260–265

    PubMed  CAS  Google Scholar 

  29. Otto M (2008) Staphylococcal biofilms. Curr Top Microbiol Immunol 322:207–228

    PubMed  CAS  Google Scholar 

  30. Skurnik D, Merighi M, Grout M, Gadjeva M, Maira-Litran T, Ericsson M, Goldmann DA, Huang SS, Datta R, Lee JC, Pier GB (2010) Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest 120(9):3220–3233

    PubMed  CAS  Google Scholar 

  31. Stauff DL, Skaar EP (2009) The heme sensor system of Staphylococcus aureus. Contrib Microbiol 16:120–135

    PubMed  CAS  Google Scholar 

  32. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, Schneewind O (2010) IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28(38):6382–6392

    PubMed  CAS  Google Scholar 

  33. Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, Towne V, Fan H, Wang XM, Wu X, Ernst R, Harvey BR, Finnefrock AC, Wang F, Tan C, Durr E, Cope L, Anderson A, An Z, McNeely T (2010) A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies 19(4):113–128

    PubMed  CAS  Google Scholar 

  34. Alksne LE, Projan SJ (2000) Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 11(6):625–636. doi:S0958-1669(00)00155-5

    PubMed  CAS  Google Scholar 

  35. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, Moss JA, Meijler MM, Ulevitch RJ, Janda KD (2007) Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14(10):1119–1127

    PubMed  CAS  Google Scholar 

  36. Otto M (2004) Quorum-sensing control in Staphylococci—a target for antimicrobial drug therapy? FEMS Microbiol Lett 241(2):135–141

    PubMed  CAS  Google Scholar 

  37. Kaneko J, Kamio Y (2004) Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 68(5):981–1003

    PubMed  CAS  Google Scholar 

  38. Bhakdi S, Tranum-Jensen J (1991) Alpha-toxin of Staphylococcus aureus. Microbiol Rev 55(4):733–751

    PubMed  CAS  Google Scholar 

  39. Liang X, Ji Y (2006) Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cell Microbiol 8(10):1656–1668

    PubMed  CAS  Google Scholar 

  40. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O (2007) Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13(12):1405–1406

    PubMed  Google Scholar 

  41. Ragle BE, Bubeck Wardenburg J (2009) Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77(7):2712–2718

    PubMed  CAS  Google Scholar 

  42. Otto M (2010) Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 64:143–162. doi:10.1146/annurev.micro.112408.134309

    PubMed  CAS  Google Scholar 

  43. Boyle-Vavra S, Daum RS (2007) Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87(1):3–9

    PubMed  CAS  Google Scholar 

  44. Diep BA, Otto M (2008) The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol 16(8):361–369

    PubMed  CAS  Google Scholar 

  45. Stryjewski ME, Chambers HF (2008) Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46(Suppl 5):S368–S377

    PubMed  CAS  Google Scholar 

  46. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B (2005) Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352(14):1445–1453

    PubMed  CAS  Google Scholar 

  47. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J (1999) Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29(5):1128–1132

    PubMed  CAS  Google Scholar 

  48. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO Jr, Kaplan SL (2006) Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 43(8):953–960

    PubMed  Google Scholar 

  49. Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE, Hammerman WA, Kaplan SL (2006) Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 117(2):433–440

    PubMed  Google Scholar 

  50. Miller LG, Diep BA (2008) Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46(5):752–760

    PubMed  CAS  Google Scholar 

  51. Yang ES, Tan J, Eells S, Rieg G, Tagudar G, Miller LG (2010) Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect 16(5):425–431

    PubMed  CAS  Google Scholar 

  52. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F (2008) Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148(4):249–257

    PubMed  Google Scholar 

  53. Laurent F, Lelievre H, Cornu M, Vandenesch F, Carret G, Etienne J, Flandrois JP (2001) Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals. J Antimicrob Chemother 47(3):277–283

    PubMed  CAS  Google Scholar 

  54. Desai R, Pannaraj PS, Agopian J, Sugar CA, Liu GY, Miller LG (2011) Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites. Am J Infect Control 39(3):219–225

    PubMed  Google Scholar 

  55. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG (2007) Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 13(2):236–242

    PubMed  Google Scholar 

  56. del Giudice P, Blanc V, de Rougemont A, Bes M, Lina G, Hubiche T, Roudiere L, Vandenesch F, Etienne J (2009) Primary skin abscesses are mainly caused by Panton-Valentine leukocidin-positive Staphylococcus aureus strains. Dermatology 219(4):299–302

    PubMed  Google Scholar 

  57. Dohin B, Gillet Y, Kohler R, Lina G, Vandenesch F, Vanhems P, Floret D, Etienne J (2007) Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus. Pediatr Infect Dis J 26(11):1042–1048

    PubMed  Google Scholar 

  58. Tseng CW, Kyme P, Low J, Rocha MA, Alsabeh R, Miller LG, Otto M, Arditi M, Diep BA, Nizet V, Doherty TM, Beenhouwer DO, Liu GY (2009) Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS One 4(7):e6387

    PubMed  Google Scholar 

  59. Yoong P, Pier GB (2010) Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci USA 107(5):2241–2246

    PubMed  CAS  Google Scholar 

  60. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Hook M, Etienne J, Vandenesch F, Bowden MG (2007) Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315(5815):1130–1133

    PubMed  CAS  Google Scholar 

  61. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR (2006) Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194(12):1761–1770

    PubMed  CAS  Google Scholar 

  62. Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J (1999) Leukocidal toxins of staphylococci. Zentralbl Bakteriol 289(2):185–201

    PubMed  CAS  Google Scholar 

  63. Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G (2010) Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 6(1):e1000715

    PubMed  Google Scholar 

  64. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF (2010) Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci USA 107(12):5587–5592

    PubMed  CAS  Google Scholar 

  65. Cremieux AC, Dumitrescu O, Lina G, Vallee C, Cote JF, uffat-Joly M, Lilin T, Etienne J, Vandenesch F, Saleh-Mghir A (2009) Panton-valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 4(9):e7204

    PubMed  Google Scholar 

  66. Lipinska U, Hermans K, Meulemans L, Dumitrescu O, Badiou C, Duchateau L, Haesebrouck F, Etienne J, Lina G (2011) Panton-Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: a rabbit model. PLoS One 6(8):e22864

    PubMed  CAS  Google Scholar 

  67. Konig B, Koller M, Prevost G, Piemont Y, Alouf JE, Schreiner A, Konig W (1994) Activation of human effector cells by different bacterial toxins (leukocidin, alveolysin, and erythrogenic toxin A): generation of interleukin-8. Infect Immun 62(11):4831–4837

    PubMed  CAS  Google Scholar 

  68. Foster SL, Hargreaves DC, Medzhitov R (2007) Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447(7147):972–978

    PubMed  CAS  Google Scholar 

  69. Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30(10):475–487

    PubMed  CAS  Google Scholar 

  70. Holland SM (2010) Chronic granulomatous disease. Clin Rev Allergy Immunol 38(1):3–10

    PubMed  CAS  Google Scholar 

  71. Ezekowitz RA, Orkin SH, Newburger PE (1987) Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 80(4):1009–1016

    PubMed  CAS  Google Scholar 

  72. Ahlin A, Larfars G, Elinder G, Palmblad J, Gyllenhammar H (1999) Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils. Clin Diagn Lab Immunol 6(3):420–424

    PubMed  CAS  Google Scholar 

  73. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (4):CD003189

  74. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24(12):1551–1557

    PubMed  CAS  Google Scholar 

  75. Mookherjee N, Hancock RE (2007) Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64(7–8):922–933

    PubMed  CAS  Google Scholar 

  76. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL (2006) Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118(4):509–519

    PubMed  CAS  Google Scholar 

  77. Buchau AS, Schauber J, Hultsch T, Stuetz A, Gallo RL (2008) Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 128(11):2646–2654

    PubMed  Google Scholar 

  78. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zugel U, Bikle DD, Modlin RL, Gallo RL (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117(3):803–811

    PubMed  CAS  Google Scholar 

  79. Beard JA, Bearden A, Striker R (2011) Vitamin D and the anti-viral state. J Clin Virol 50(3):194–200

    PubMed  CAS  Google Scholar 

  80. Gibney KB, MacGregor L, Leder K, Torresi J, Marshall C, Ebeling PR, Biggs BA (2008) Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 46(3):443–446

    PubMed  CAS  Google Scholar 

  81. Matheson EM, Mainous AG 3rd, Hueston WJ, Diaz VA, Everett CJ (2010) Vitamin D and methicillin-resistant Staphylococcus aureus nasal carriage. Scand J Infect Dis 42(6–7):455–460

    PubMed  CAS  Google Scholar 

  82. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532–1535

    PubMed  CAS  Google Scholar 

  83. Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, Nizet V (2010) Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8(5):445–454

    PubMed  CAS  Google Scholar 

  84. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169(18):1658–1667

    PubMed  Google Scholar 

  85. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Donini O, Guarna MM, Finlay BB, North JR, Hancock RE (2007) An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 25(4):465–472

    PubMed  CAS  Google Scholar 

  86. Lee HY, Bae YS (2008) The anti-infective peptide, innate defense-regulator peptide, stimulates neutrophil chemotaxis via a formyl peptide receptor. Biochem Biophys Res Commun 369(2):573–578

    PubMed  CAS  Google Scholar 

  87. McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, Ishii KJ, Akira S, Colonna M, Chen ZJ, Fitzgerald KA, Hayakawa Y, Vance RE (2009) A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 206(9):1899–1911

    PubMed  CAS  Google Scholar 

  88. Karaolis DK, Means TK, Yang D, Takahashi M, Yoshimura T, Muraille E, Philpott D, Schroeder JT, Hyodo M, Hayakawa Y, Talbot BG, Brouillette E, Malouin F (2007) Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178(4):2171–2181

    PubMed  CAS  Google Scholar 

  89. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, Hurtado-Ziola N, Nizet V, Johnson RS (2005) HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 115(7):1806–1815

    PubMed  CAS  Google Scholar 

  90. Zinkernagel AS, Peyssonnaux C, Johnson RS, Nizet V (2008) Pharmacologic augmentation of hypoxia-inducible factor-1alpha with mimosine boosts the bactericidal capacity of phagocytes. J Infect Dis 197(2):214–217

    PubMed  CAS  Google Scholar 

  91. Gombart AF, Koeffler HP (2002) Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). Curr Opin Hematol 9(1):36–42

    PubMed  Google Scholar 

  92. Niren NM (2006) Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis 77(1 Suppl):11–16

    PubMed  Google Scholar 

  93. Szabo C (2003) Nicotinamide: a jack of all trades (but master of none?). Intensive Care Med 29(6):863–866

    PubMed  Google Scholar 

  94. Murray MF (2003) Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Clin Infect Dis 36(4):453–460

    PubMed  CAS  Google Scholar 

  95. St John RC, Dorinsky PM (1993) Immunologic therapy for ARDS, septic shock, and multiple-organ failure. Chest 103(3):932–943

    PubMed  CAS  Google Scholar 

  96. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783–801

    PubMed  CAS  Google Scholar 

  97. Ting JP, Duncan JA, Lei Y (2010) How the noninflammasome NLRs function in the innate immune system. Science 327(5963):286–290

    PubMed  CAS  Google Scholar 

  98. Stenzel W, Soltek S, Sanchez-Ruiz M, Akira S, Miletic H, Schluter D, Deckert M (2008) Both TLR2 and TLR4 are required for the effective immune response in Staphylococcus aureus-induced experimental murine brain abscess. Am J Pathol 172(1):132–145

    PubMed  CAS  Google Scholar 

  99. Takeuchi O, Hoshino K, Akira S (2000) Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165(10):5392–5396

    PubMed  CAS  Google Scholar 

  100. Miller LS, O'Connell RM, Gutierrez MA, Pietras EM, Shahangian A, Gross CE, Thirumala A, Cheung AL, Cheng G, Modlin RL (2006) MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 24(1):79–91

    PubMed  CAS  Google Scholar 

  101. Deshmukh HS, Hamburger JB, Ahn SH, McCafferty DG, Yang SR, Fowler VG Jr (2009) Critical role of NOD2 in regulating the immune response to Staphylococcus aureus. Infect Immun 77(4):1376–1382

    PubMed  CAS  Google Scholar 

  102. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN (2010) Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 16(2):228–231

    PubMed  CAS  Google Scholar 

  103. Church LD, Cook GP, McDermott MF (2008) Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 4(1):34–42

    PubMed  CAS  Google Scholar 

  104. Hultgren OH, Svensson L, Tarkowski A (2002) Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol 168(10):5207–5212

    PubMed  CAS  Google Scholar 

  105. Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H, O'Connell RM, Iwakura Y, Cheung AL, Cheng G, Modlin RL (2007) Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol 179(10):6933–6942

    PubMed  CAS  Google Scholar 

  106. Shimada T, Park BG, Wolf AJ, Brikos C, Goodridge HS, Becker CA, Reyes CN, Miao EA, Aderem A, Gotz F, Liu GY, Underhill DM (2010) Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe 7(1):38–49

    PubMed  CAS  Google Scholar 

  107. Yu HB, Finlay BB (2008) The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe 4(3):198–208

    PubMed  CAS  Google Scholar 

  108. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA (1995) Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267(5206):2000–2003

    PubMed  CAS  Google Scholar 

  109. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10(3):241–247

    PubMed  CAS  Google Scholar 

  110. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC (2006) CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci USA 103(27):10408–10413

    PubMed  CAS  Google Scholar 

  111. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS (2010) IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120(5):1762–1773

    PubMed  Google Scholar 

  112. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F (2009) T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65(5):499–509

    PubMed  CAS  Google Scholar 

  113. Mudter J, Neurath MF (2007) Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13(8):1016–1023

    PubMed  Google Scholar 

  114. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11(4):443–451

    PubMed  CAS  Google Scholar 

  115. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, Boneca IG (2004) Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 5(10):1000–1006

    PubMed  CAS  Google Scholar 

  116. Molne L, Verdrengh M, Tarkowski A (2000) Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun 68(11):6162–6167

    PubMed  CAS  Google Scholar 

  117. Hruz P, Zinkernagel AS, Jenikova G, Botwin GJ, Hugot JP, Karin M, Nizet V, Eckmann L (2009) NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation. Proc Natl Acad Sci USA 106(31):12873–12878

    PubMed  CAS  Google Scholar 

  118. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278(8):5509–5512

    PubMed  CAS  Google Scholar 

  119. Volz T, Nega M, Buschmann J, Kaesler S, Guenova E, Peschel A, Rocken M, Gotz F, Biedermann T (2010) Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J 24(10):4089–4102

    PubMed  CAS  Google Scholar 

  120. Bera A, Herbert S, Jakob A, Vollmer W, Gotz F (2005) Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 55(3):778–787

    PubMed  CAS  Google Scholar 

  121. Ginsburg I (2002) Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2(3):171–179

    PubMed  CAS  Google Scholar 

  122. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, Schumann RR (2003) Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 278(18):15587–15594

    PubMed  Google Scholar 

  123. Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, Krikae F, Kirikae T, Gotz F (2006) Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol 177(5):3162–3169

    PubMed  CAS  Google Scholar 

  124. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, Wu ZR, Hooper LV, Schmidt RR, von Aulock S, Radek KA, Huang CM, Ryan AF, Gallo RL (2009) Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 15(12):1377–1382

    PubMed  CAS  Google Scholar 

  125. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG, Fischer GW (2009) Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 53(7):2879–2886

    PubMed  CAS  Google Scholar 

  126. Schmaler M, Jann NJ, Ferracin F, Landolt LZ, Biswas L, Gotz F, Landmann R (2009) Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-dependent growth in vivo. J Immunol 182(11):7110–7118

    PubMed  CAS  Google Scholar 

  127. Bubeck Wardenburg J, Williams WA, Missiakas D (2006) Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc Natl Acad Sci USA 103(37):13831–13836

    PubMed  Google Scholar 

  128. Bueno C, Criado G, McCormick JK, Madrenas J (2007) T cell signalling induced by bacterial superantigens. Chem Immunol Allergy 93:161–180

    PubMed  CAS  Google Scholar 

  129. Hong-Geller E, Gupta G (2003) Therapeutic approaches to superantigen-based diseases: a review. J Mol Recognit 16(2):91–101

    PubMed  CAS  Google Scholar 

  130. Chau TA, McCully ML, Brintnell W, An G, Kasper KJ, Vines ED, Kubes P, Haeryfar SM, McCormick JK, Cairns E, Heinrichs DE, Madrenas J (2009) Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat Med 15(6):641–648

    PubMed  CAS  Google Scholar 

  131. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13(12):1510–1514

    PubMed  CAS  Google Scholar 

  132. Kretschmer D, Gleske AK, Rautenberg M, Wang R, Koberle M, Bohn E, Schoneberg T, Rabiet MJ, Boulay F, Klebanoff SJ, van Kessel KA, van Strijp JA, Otto M, Peschel A (2010) Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. Cell Host Microbe 7(6):463–473

    PubMed  CAS  Google Scholar 

  133. McElroy MC, Harty HR, Hosford GE, Boylan GM, Pittet JF, Foster TJ (1999) Alpha-toxin damages the air-blood barrier of the lung in a rat model of Staphylococcus aureus-induced pneumonia. Infect Immun 67(10):5541–5544

    PubMed  CAS  Google Scholar 

  134. Seeger W, Birkemeyer RG, Ermert L, Suttorp N, Bhakdi S, Duncker HR (1990) Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest 63(3):341–349

    PubMed  CAS  Google Scholar 

  135. Wilke GA, Bubeck Wardenburg J (2010) Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci USA 107(30):13473–13478

    PubMed  CAS  Google Scholar 

  136. Munoz-Planillo R, Franchi L, Miller LS, Nunez G (2009) A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 183(6):3942–3948

    PubMed  CAS  Google Scholar 

  137. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081):228–232

    PubMed  CAS  Google Scholar 

  138. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA (2009) Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4(10):e7446

    PubMed  Google Scholar 

  139. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, Silverman GJ (2000) Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 97(10):5399–5404

    PubMed  CAS  Google Scholar 

  140. Goodyear CS, Silverman GJ (2004) Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci USA 101(31):11392–11397

    PubMed  CAS  Google Scholar 

  141. Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A, Prince A (2004) Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 10(8):842–848

    PubMed  CAS  Google Scholar 

  142. Terada M, Tsutsui H, Imai Y, Yasuda K, Mizutani H, Yamanishi K, Kubo M, Matsui K, Sano H, Nakanishi K (2006) Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci USA 103(23):8816–8821

    PubMed  CAS  Google Scholar 

  143. McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, Perez CM (1997) Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 278(11):925–931

    PubMed  CAS  Google Scholar 

  144. de Gans J, van de Beek D (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347(20):1549–1556

    PubMed  Google Scholar 

  145. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J (2006) Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 58(1):117–124

    PubMed  CAS  Google Scholar 

  146. Coyle EA (2003) Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 23(5):638–642

    CAS  Google Scholar 

  147. Sprunt K, Leidy G (1988) The use of bacterial interference to prevent infection. Can J Microbiol 34(3):332–338

    PubMed  CAS  Google Scholar 

  148. Brook I (1999) Bacterial interference. Crit Rev Microbiol 25(3):155–172

    PubMed  CAS  Google Scholar 

  149. Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T (2011) Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev (3):CD005496

  150. Bakken JS (2009) Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15(6):285–289

    PubMed  Google Scholar 

  151. von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344(1):11–16

    Google Scholar 

  152. Lederer SR, Riedelsdorf G, Schiffl H (2007) Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res 12(7):284–288

    PubMed  CAS  Google Scholar 

  153. Coates T, Bax R, Coates A (2009) Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 64(1):9–15

    PubMed  CAS  Google Scholar 

  154. Patel JB, Gorwitz RJ, Jernigan JA (2009) Mupirocin resistance. Clin Infect Dis 49(6):935–941

    PubMed  CAS  Google Scholar 

  155. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5(12):751–762

    PubMed  Google Scholar 

  156. Shinefield HR, Ribble JC, Boris M, Eichenwald HF, Aly R, Maibach H (1974) Bacterial interference between strains of S. aureus. Ann N Y Acad Sci 236:444–455

    PubMed  CAS  Google Scholar 

  157. Uehara Y, Nakama H, Agematsu K, Uchida M, Kawakami Y, Abdul Fattah AS, Maruchi N (2000) Bacterial interference among nasal inhabitants: eradication of Staphylococcus aureus from nasal cavities by artificial implantation of Corynebacterium sp. J Hosp Infect 44(2):127–133

    PubMed  CAS  Google Scholar 

  158. Lina G, Boutite F, Tristan A, Bes M, Etienne J, Vandenesch F (2003) Bacterial competition for human nasal cavity colonization: role of Staphylococcal agr alleles. Appl Environ Microbiol 69(1):18–23

    PubMed  CAS  Google Scholar 

  159. Uehara Y, Kikuchi K, Nakamura T, Nakama H, Agematsu K, Kawakami Y, Maruchi N, Totsuka K (2001) Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group streptococci. Clin Infect Dis 32(10):1399–1407

    PubMed  CAS  Google Scholar 

  160. Mackowiak PA (1982) The normal microbial flora. N Engl J Med 307(2):83–93. doi:10.1056/NEJM198207083070203

    PubMed  CAS  Google Scholar 

  161. Kiser KB, Cantey-Kiser JM, Lee JC (1999) Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect Immun 67(10):5001–5006

    PubMed  CAS  Google Scholar 

  162. Bibel DJ, Aly R, Bayles C, Strauss WG, Shinefield HR, Maibach HI (1983) Competitive adherence as a mechanism of bacterial interference. Can J Microbiol 29(6):700–703

    PubMed  CAS  Google Scholar 

  163. Gan BS, Kim J, Reid G, Cadieux P, Howard JC (2002) Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 185(9):1369–1372

    PubMed  Google Scholar 

  164. Gillor O, Etzion A, Riley MA (2008) The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol 81(4):591–606

    PubMed  CAS  Google Scholar 

  165. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A (2004) Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54(3):648–653

    PubMed  CAS  Google Scholar 

  166. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47(5):1589–1597

    PubMed  CAS  Google Scholar 

  167. Park B, Nizet V, Liu GY (2008) Role of Staphylococcus aureus catalase in niche competition against Streptococcus pneumoniae. J Bacteriol 190(7):2275–2278

    PubMed  CAS  Google Scholar 

  168. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M (2006) Interference between Streptococcus pneumoniae and Staphylococcus aureus: in vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. J Bacteriol 188(13):4996–5001

    PubMed  CAS  Google Scholar 

  169. Pericone CD, Overweg K, Hermans PW, Weiser JN (2000) Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun 68(7):3990–3997

    PubMed  CAS  Google Scholar 

  170. Uehara Y, Kikuchi K, Nakamura T, Nakama H, Agematsu K, Kawakami Y, Maruchi N, Totsuka K (2001) H(2)O(2) produced by viridans group streptococci may contribute to inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns. Clin Infect Dis 32(10):1408–1413

    PubMed  CAS  Google Scholar 

  171. Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, Derazne E, Rahav G, Rubinstein E (2004) Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA 292(6):716–720

    PubMed  CAS  Google Scholar 

  172. Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2(10):820–832

    PubMed  CAS  Google Scholar 

  173. Selva L, Viana D, Regev-Yochay G, Trzcinski K, Corpa JM, Lasa I, Novick RP, Penades JR (2009) Killing niche competitors by remote-control bacteriophage induction. Proc Natl Acad Sci USA 106(4):1234–1238

    PubMed  CAS  Google Scholar 

  174. Ji G, Beavis R, Novick RP (1997) Bacterial interference caused by autoinducing peptide variants. Science 276(5321):2027–2030

    PubMed  CAS  Google Scholar 

  175. Goerke C, Kummel M, Dietz K, Wolz C (2003) Evaluation of intraspecies interference due to agr polymorphism in Staphylococcus aureus during infection and colonization. J Infect Dis 188(2):250–256

    PubMed  CAS  Google Scholar 

  176. Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, Agata T, Mizunoe Y (2010) Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465(7296):346–349

    PubMed  CAS  Google Scholar 

  177. Lysenko ES, Ratner AJ, Nelson AL, Weiser JN (2005) The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 1(1):e1

    PubMed  Google Scholar 

  178. Park B, Iwase T, Liu GY (2011) Intranasal Application of S. epidermidis Prevents Colonization by Methicillin-Resistant Staphylococcus aureus in Mice. PLoS One. 6(10):e25880

    Google Scholar 

  179. Pishchany G, McCoy AL, Torres VJ, Krause JC, Crowe JE Jr, Fabry ME, Skaar EP (2010) Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 8(6):544–550

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a Burroughs-Wellcome Career Award and by National Institutes of Health grant AI074832 to G. Y. Liu.

Author information

Affiliations

  1. Division of Pediatric Infectious Diseases and the Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA

    Bonggoo Park & George Y. Liu

Authors
  1. Bonggoo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Y. Liu.

Additional information

This article is published as part of the Special Issue on Immunopathology of staphylococcal infections [34:3]

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Park, B., Liu, G.Y. Targeting the host–pathogen interface for treatment of Staphylococcus aureus infection. Semin Immunopathol 34, 299–315 (2012). https://doi.org/10.1007/s00281-011-0297-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-011-0297-1

Keywords

  • S. aureus
  • MRSA
  • Virulence
  • Antibiotic resistance
  • Probiotics
  • Inflammation